A Retrospective Investigation of Local Anesthetic Concentrations in Femoral Nerve Block
A Retrospective Investigation of Safety and Efficacy From Increasing Concentrations of Local Anesthetic in Pediatric Femoral Nerve Blocks
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- ASA physical status I or II
- Age < or equal to 18 years of age at time of femoral nerve block
- Femoral nerve block performed from 2010-2015
Exclusion Criteria:
- ASA physical status > II
- Co-morbid diseases (cardiac, pulmonary, neurological disease)
- Use of adjunctive medications in femoral nerve block (except for epinephrine), such as dexamethasone
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Femoral Nerve Blocks
Patients who receive ropivacaine or bupivacaine during femoral nerve block.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Concentration of Local Anesthetic Injected for Femoral Nerve Block
Time Frame: length of surgery
|
length of surgery
|
|
|
Total mg of Local Anesthetic Injected for Femoral Nerve Block
Time Frame: length of surgery
|
length of surgery
|
|
|
Intraoperative Tylenol Administered
Time Frame: length of surgery
|
Amount of Tylenol administered based on if got ropivacaine or bupivacaine femeral nerve block.
|
length of surgery
|
|
Post-operative Opioids Administered
Time Frame: in PACU (1 hr post-op)
|
Amount of opioid consumption in the post operative anesthesia care unit depending on if the patient received femoral nerve block with ropivacaine or bupivacaine
|
in PACU (1 hr post-op)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Time to Discharge From PACU
Time Frame: Conclusion of surgery until admission to assigned unit or to phase, an expected average of 1 hour
|
Conclusion of surgery until admission to assigned unit or to phase, an expected average of 1 hour
|
|
|
Post-operative Pain Scale Using FLACC
Time Frame: 1 hour post-op
|
The Face, Legs, Activity, Cry, Consolability scale or FLACC scale is a measurement used to assess pain for children between the ages of 2 months and 7 years or individuals that are unable to communicate their pain.
The scale is scored in a range of 0-10 with 0 representing no pain.
|
1 hour post-op
|
|
Post-operative Pain Scale Using VAS
Time Frame: 1 hour post-op
|
The visual analogue scale (VAS) for pain is a validated, subjective measure where scores are recorded by making a handwritten mark on a 10-cm line that represents a continuum between "no pain" and "worst pain."
|
1 hour post-op
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Giorgio Veneziano, MD, Nationwide Children's Hospital
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- IRB 15-00396
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.